Orchard Therapeutics Plc (ORTX) Misses Q2 EPS by 6c

Orchard Therapeutics Plc (NASDAQ: ORTX) reported Q2 EPS of ($0.48), $0.06 worse than the analyst estimate of ($0.42).

“Implementing Orchard’s new strategic plan yielded strong results in the second quarter as we marked important regulatory and clinical progress in our neurometabolic programs and strengthened our current and future manufacturing position,” said Bobby Gaspar, M.D., Ph.D., chief executive officer of Orchard. “Our commercial infrastructure and launch plans continue to develop with a focus on site qualification, diagnostic initiatives, pricing and reimbursement as we prepare for the potential approval of Libmeldy (formerly OTL-200) in the EU. Towards the end of the year, we plan to share more detail from our new research programs in FTD and Crohn’s disease, which we believe highlight the potential for HSC gene therapy beyond ultra-rare diseases.”

For earnings history and earnings-related data on Orchard Therapeutics Plc (ORTX) click here.

You May Also Be Interested In

• Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
• Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
• CPS Technologies (CPSH) Reports In-Line Q3 EPS